Skip to main content
Clinical Trials/JPRN-jRCT1041190125
JPRN-jRCT1041190125
Recruiting
未知

Patient REported, Clinical, and Imaging OUtcomes of tapering methotrexate in patients with rheumatoid arthritis in Stable low disease activity with Baricitinib - PRECIOUS-B study

Asai Shuji0 sites51 target enrollmentMarch 9, 2020

Overview

Phase
未知
Intervention
Not specified
Conditions
Rheumatoid arthritis
Sponsor
Asai Shuji
Enrollment
51
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
March 9, 2020
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Asai Shuji

Eligibility Criteria

Inclusion Criteria

  • 1\) Patients fulfilled the 1987 ACR classification criteria or the new ACR/EULAR diagnostic criteria for RA
  • 2\) RA patients with sustained low disease activity (CDAI \<\=10\) for \>\=12 weeks while undergoing combination therapy with BAR plus MTX
  • 3\) RA patients receiving BAR, MTX, csDMARDs, and glucocorticoids at a stable dosage regimen for \>\=12 weeks prior to obtaining informed consent
  • 4\) RA patients aged \>\=20 years
  • 5\) Obtaining written informed consent

Exclusion Criteria

  • 1\) Patients with adherence problems
  • 2\) Patients judged as inadequate at the discretion of inevstigators

Outcomes

Primary Outcomes

Not specified

Similar Trials